Alison Silva, Synlogic

28 Pages·2016·3.66 MB·English

Corporate & PKU Overview
February 2016
Corporate History
2017 UCD & PKU Programs: Ph1b Data
[ YE2016/1H2017 ]
IND Filing
2016
December 2015:
July 2015:
$40M Series B round TS signed
IBD collaboration signed with AbbVie
2015
November 2014:
Start of lab operations
July/October 2014:
$29.4M Series A round: Atlas Ventures,
NEA, and B&M Gates Foundation)
2014
Scientific
Co-Founders:
Dr. James
Collins & Dr. March 2013:
Timothy Lu Synlogic Incorporated (fkaTMC
Therapeutics; seeded at Atlas Venture)
2013
2 2
S B : Precision Programmed Probiotics
YNTHETIC IOTICS
to Treat Serious Diseases
Synthetic
Biotics
Selective and predictable
pharmacology
Precision
Programming Designed to be safe
Oral administration
Designed to perform
metabolic functions in the
gut to treat diseases
400+ $3.5 B
species of sales probiotic
probiotics in supplements &
our body products, U.S.* (2015)
*Statista 2016
3
Synthetic Biotics: A New Class of Drugs
Synthetic Biotics
• Engineered bacteria
• Probiotic bacteria: E. coli Nissle
• Genetic circuits that perform
• Derived from natural human
metabolic transformations
microbiome
• Designed synthetically to degrade
• Extensive safety in humans as
metabolites that induce disease
probiotic
or synthesize substances that
• Daily, oral administration
can treat disease
Synthetic Biotics
Therapeutic action from
the microbiome to correct
metabolic dysregulation
throughout the body
4
Synthetic Biotics: Therapeutics that Operate from
our Natural Microbiome
Synlogic's synthetic biotics
are oral bacterial drug products
that blend with the patient
microbiome where they perform
their programmed therapeutic
metabolic transformations …
…. to correct metabolite
dysregulation that is causing
chronic disease throughout the
body
5
Synlogic is at the Convergence of Two Revolutionary
Fields in Life Sciences
2 Revolutionary Fields
Synthetic Biology Microbiome
Probiotic
Synthetic Biotics
• Transformative therapies
• Pipeline of products
• Value Creation in compressed timeline
Rare Major
Diseases Diseases
Therapeutic Drug Products
6
Synlogic’s Drug Discovery and Development Approach
Inborn
Errors of
✓
Metabolism
Genetic circuits Synthetic
specialized in Biotic
metabolic
transformations
Correct the
deficiency
Probiotic bacteria:
E. coli Nissle
7
A Simple, Robust and Rapid Platform for
Generating Synthetic Biotics
DEFINE
DISEASE PATHWAY
DESIGN ASSIMILATE
CIRCUIT IN THE MICROBIOME
BUILD
SYNTHETIC BIOTIC
• Metabolic pathway • Genetic circuits • Bacterial engineering • System check
expertise • Switches • “Chassis” optimization • GI dynamics
• Drug development • Bacterial technologies • Bacterial genome • Potency in vitro and in
experience • Enzyme selection integration landing vivo
• Understanding of pads • Blend into microbiome
• Genomic integration
disease processes technologies • Stable integration without colonization
• Differentiated TPP
8
Synlogic’s Initial Focus: Inborn Errors of Metabolism
Disease Toxic Metabolite
Urea Cycle Disorders Ammonia
Phenylketonuria Phenylalanine
Organic Acidemias Propionate
Maple Syrup Urine
Ile, Leu, Val
Disease
Homocysteine,
Homocysteinuria
Methionine
Xanthinuria Type 1 Xanthine
Primary Hyperoxaluria Oxalate
9
Synthetic Biotics Can Mediate Broad-Range of
Metabolite Transformations in the Gut
Phenylketonuria AMINO ACID METABOLISM
(PKU)
Phenylalanine
Oncology
Leucine
Aging
Maple Syrup
Isoleucine
Urinary disease
Valine
(MSUD)
Enabling SHORT AND MEDIUM CHAIN
for broader FATTY ACID METABOLISM
pathway
Organic
applications
Propionate Inflammation
Acidemias in the gut
Butyrate Autoimmune & Metabolic Disease
TOXIC METABOLITE
CONVERSION
Urea Cycle
Ammonia
Liver Disease
Disorders
Chronic Kidney Disease
Oncology Detoxification
10